Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 20Terminated 7Unknown 4Withdrawn 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1

Interventions

Cyclophosphamide 17Rituximab 12Prednisone 7Peripheral Blood Stem Cell Transplantation 7Filgrastim 7sargramostim 6Vincristine 6fludarabine phosphate 5Radiotherapy 5Doxorubicin 5Cytarabine 5Cisplatin 5ibritumomab tiuxetan 4Methylprednisolone 4Melphalan 4Etoposide 4Dexamethasone 4Cyclosporine 4epratuzumab 3Sensitivity and Specificity 3Polymerase Chain Reaction 3Mycophenolic Acid 3Indium 3Chlorambucil 3Busulfan 3Bendamustine Hydrochloride 3Antilymphocyte Serum 3Antigens, CD19 3obinutuzumab 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Follicular × ibritumomab tiuxetan × Clear all
NCT01827605 2023-12-14

A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)

Fondazione Italiana Linfomi - ETS

Phase 3 Unknown
159 enrolled
Lymphoid

Lymphoma, Follicular

NCT00397800 2012-08-28

Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

Technical University of Munich

Phase 1/2 Unknown
12 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00772655 2012-08-02

Zevalin® First Line in Follicular Lymphoma

Charite University, Berlin, Germany

Phase 2 Unknown
60 enrolled
Lymphoid

Lymphoma, Follicular

NCT00722930 2008-07-28

GOTEL-FL1LC

Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas

Phase 2 Unknown
38 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡